Journal article
Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial—Clinical outcomes and molecular determinants of response
C Murphy, A Muscat, D Ashley, V Mukaro, L West, Y Liao, D Chisanga, W Shi, I Collins, S Baron-Hay, S Patil, G Lindeman, M Khasraw
Plos One | PUBLIC LIBRARY SCIENCE | Published : 2019
Abstract
Background This study evaluated the feasibility of achieving high response rates in stage II or III breast cancer by tailoring neoadjuvant therapy using clinical and histopathological features and the Oncotype DX Breast Recurrence Score. Genomic determinants of response and resistance were also explored. Patients and outcome measures Fifty-one patients were enrolled. The primary cohort comprised 40 patients: 15 human epidermal growth factor receptor type 2 (HER2)-amplified; 15 triple-negative (TNBC); and ten hormone receptor (HR)-positive, HER2-non-amplified tumours; with recurrence scores 25. Patients were treated with epirubicin and cyclophosphamide, followed by nab-paclitaxel, with the ad..
View full abstractGrants
Awarded by United Therapeutics Corporation
Funding Acknowledgements
This study was funded by an unrestricted research grant from Specialised Therapeutics Australia, a National Medical Health and Research Council of Australia Centre of Research Excellence Grant (#1040978) and a Tuck Family Scholarship. Lake Imaging, Geelong, VIC, Australia provided support in the form of a salary for author LW. These funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. We would like to thank Christoffer Flensburg and Christophe Lefevre for their help in clonality analysis. WS is supported by a Walter and Eliza Hall Institute Centenary Fellowship sponsored by CSL.